281 related articles for article (PubMed ID: 17680034)
21. Electronic structure of bent titanocene complexes with chelated dithiolate ligands.
Cooney JJ; Cranswick MA; Gruhn NE; Joshi HK; Enemark JH
Inorg Chem; 2004 Dec; 43(25):8110-8. PubMed ID: 15578851
[TBL] [Abstract][Full Text] [Related]
22. Titanocene anticancer complexes and their binding mode of action to human serum albumin: a computational study.
Sarsam SW; Nutt DR; Strohfeldt K; Watson KA
Metallomics; 2011 Feb; 3(2):152-61. PubMed ID: 21210044
[TBL] [Abstract][Full Text] [Related]
23. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay.
Weber H; Claffey J; Hogan M; Pampillón C; Tacke M
Toxicol In Vitro; 2008 Mar; 22(2):531-4. PubMed ID: 17981007
[TBL] [Abstract][Full Text] [Related]
24. A (1)H NMR study of the interaction of antitumor metallocenes with glutathione.
Mokdsi G; Harding MM
J Inorg Biochem; 2001 Sep; 86(2-3):611-6. PubMed ID: 11566334
[TBL] [Abstract][Full Text] [Related]
25. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Sun H; McArdle HJ; Gambling L; Sadler PJ
Biochemistry; 2000 Aug; 39(33):10023-33. PubMed ID: 10955990
[TBL] [Abstract][Full Text] [Related]
26. Unexpected influence of stereochemistry on the cytotoxicity of highly efficient Ti(IV) salan complexes: new mechanistic insights.
Manna CM; Armony G; Tshuva EY
Chemistry; 2011 Dec; 17(50):14094-103. PubMed ID: 22076809
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
Chimento A; Saturnino C; Iacopetta D; Mazzotta R; Caruso A; Plutino MR; Mariconda A; Ramunno A; Sinicropi MS; Pezzi V; Longo P
Bioorg Med Chem; 2015 Nov; 23(22):7302-12. PubMed ID: 26526741
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, Ti(IV) intake by apotransferrin and cytotoxic properties of functionalized titanocene dichlorides.
Gao LM; Hernández R; Matta J; Meléndez E
J Biol Inorg Chem; 2007 Sep; 12(7):959-67. PubMed ID: 17566797
[TBL] [Abstract][Full Text] [Related]
30. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents.
Pampillón C; Claffey J; Strohfeldt K; Tacke M
Eur J Med Chem; 2008 Jan; 43(1):122-8. PubMed ID: 17412456
[TBL] [Abstract][Full Text] [Related]
32. Coordination Complexes of Titanium(IV) for Anticancer Therapy.
Tshuva EY; Miller M
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394027
[TBL] [Abstract][Full Text] [Related]
33. Antitumor titanium compounds.
Caruso F; Rossi M
Mini Rev Med Chem; 2004 Jan; 4(1):49-60. PubMed ID: 14754443
[TBL] [Abstract][Full Text] [Related]
34. Anti-cancer applications of titanocene-functionalised nanostructured systems: an insight into cell death mechanisms.
Ceballos-Torres J; Virag P; Cenariu M; Prashar S; Fajardo M; Fischer-Fodor E; Gómez-Ruiz S
Chemistry; 2014 Aug; 20(34):10811-28. PubMed ID: 24715574
[TBL] [Abstract][Full Text] [Related]
35. Water-soluble titanocene complexes with sulfur-containing amino acids: synthesis, spectroscopic, electrochemical and Ti(IV)-transferrin interaction studies.
Pérez Y; López V; Rivera-Rivera L; Cardona A; Meléndez E
J Biol Inorg Chem; 2005 Mar; 10(2):94-104. PubMed ID: 15619089
[TBL] [Abstract][Full Text] [Related]
36. Dimethyl titanocene Y: a valuable precursor for libraries of cytotoxic titanocene derivatives.
Immel TA; Martin JT; Dürr CJ; Groth U; Huhn T
J Inorg Biochem; 2010 Aug; 104(8):863-7. PubMed ID: 20452674
[TBL] [Abstract][Full Text] [Related]
37. Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Guo Z; Sadler PJ
J Biol Inorg Chem; 2001 Sep; 6(7):698-707. PubMed ID: 11681703
[TBL] [Abstract][Full Text] [Related]
38. Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs.
Allen OR; Gott AL; Hartley JA; Hartley JM; Knox RJ; McGowan PC
Dalton Trans; 2007 Nov; (43):5082-90. PubMed ID: 17992293
[TBL] [Abstract][Full Text] [Related]
39. Metals and metal compounds in cancer treatment.
Desoize B
Anticancer Res; 2004; 24(3a):1529-44. PubMed ID: 15274320
[TBL] [Abstract][Full Text] [Related]
40. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
Tacke M; Cuffe LP; Gallagher WM; Lou Y; Mendoza O; Müller-Bunz H; Rehmann FJ; Sweeney N
J Inorg Biochem; 2004 Dec; 98(12):1987-94. PubMed ID: 15541486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
